



OPEN ACCESS

## TRANSLATIONAL SCIENCE

# Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis

Bora Nam <sup>1,2</sup>, Sungsin Jo <sup>2</sup>, So-Young Bang <sup>1,2</sup>, Youngho Park,<sup>3</sup> Ji Hui Shin,<sup>1</sup> Ye-Soo Park,<sup>4</sup> Seunghun Lee,<sup>5</sup> Kyung Bin Joo,<sup>2</sup> Tae-Hwan Kim <sup>1,2</sup>

**Handling editor** Josef S Smolen

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ard-2022-222796>).

<sup>1</sup>Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

<sup>2</sup>Hanyang University Institute for Rheumatology Research (HYIRR), Seoul, South Korea

<sup>3</sup>Department of Big Data Application College of Smart Convergence, Hannam University, Daejeon, South Korea

<sup>4</sup>Department of Orthopaedic Surgery, Hanyang University College of Medicine, Guri Hospital, Guri, South Korea

<sup>5</sup>Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

## Correspondence to

Dr Tae-Hwan Kim, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, South Korea; [thkim@hanyang.ac.kr](mailto:thkim@hanyang.ac.kr)

BN and SJ contributed equally.

BN and SJ are joint first authors.

Received 13 May 2022

Accepted 13 December 2022

Published Online First

21 December 2022



Check for updates

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Nam B, Jo S, Bang S-Y, et al. Ann Rheum Dis 2023;82:527–532.

BMJ

## ABSTRACT

**Objectives** To identify clinical and genetic factors associated with severe radiographic damage in patients with ankylosing spondylitis (AS).

**Methods** We newly generated genome-wide single nucleotide polymorphism data (833K) for 444 patients with AS. The severity of radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). To identify clinical and genetic factors associated with severe radiographic damage, multiple linear regression analyses were performed. Human AS-osteoprogenitor and control-osteoprogenitor cells were used for functional validation.

**Results** The significant clinical factors of final mSASSS were baseline mSASSS ( $\beta=0.796$ ,  $p=3.22\times 10^{-75}$ ), peripheral joint arthritis ( $\beta=-0.246$ ,  $p=6.85\times 10^{-6}$ ), uveitis ( $\beta=0.157$ ,  $p=1.95\times 10^{-3}$ ), and smoking ( $\beta=0.130$ ,  $p=2.72\times 10^{-2}$ ) after adjusting for sex, age and disease duration. After adjusting significant clinical factors, the *Ryanodine receptor 3* (*RYR3*) gene was associated with severe radiographic damage ( $p=1.00\times 10^{-6}$ ). For pathway analysis, the PI3K-Akt signalling pathway was associated with severe radiographic damage in AS ( $p=2.21\times 10^{-4}$ , false discovery rate=0.040). Treatment with rhodamine B, a ligand of RYR3, dose-dependently induced matrix mineralisation of AS osteoprogenitors. However, the rhodamine B-induced accelerated matrix mineralisation was not definitive in control osteoprogenitors. Knockdown of RYR3 inhibited matrix mineralisation in SaOS2 cell lines.

**Conclusions** This study identified clinical and genetic factors that contributed to better understanding of the pathogenesis and biology associated with radiographic damage in AS.

## INTRODUCTION

Ankylosing spondylitis (AS) is a heritable inflammatory disease eventually leading to spinal fusion.<sup>1</sup> A genome-wide association study (GWAS) is a hypothesis-free approach to identify genetic variants underlying disease. GWAS has led to valuable insights into the complex genetic background of autoimmune disease.<sup>2</sup> Since the first GWAS for AS was published,<sup>3</sup> aminopeptidases such as *endoplasmic reticulum aminopeptidase* (ERAP) 1 and ERAP2, and genes in the tumour necrosis factor and interleukin (IL)-23 pathways have been identified as AS-associated genetic variants through subsequent GWAS and Immunochip studies.<sup>4,5</sup>

However, most previous genetic studies for AS have only focused on disease susceptibility.

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Ankylosing spondylitis (AS) is an inflammatory rheumatic disease characterised by progressive spinal damage.
- ⇒ The severity of spinal damage is highly variable among individuals and can be affected by both clinical and genetic factors.
- ⇒ Most genome-wide association studies for AS have only focused on disease susceptibility rather than radiographic damage.

## WHAT THIS STUDY ADDS

- ⇒ We identified the *RYR3* gene as a novel candidate gene for severe radiographic damage in AS.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Our results can provide new insights on the underlying pathogenesis of spinal damage in AS and open new avenues for better personalised medicine by identifying high-risk patients of severe structural damage.

Genetic studies targeting radiographic damage remain limited. Only a few candidate gene studies showed meaningful results, including *HLA-B\*4100*, *DRB1\*0804*, *DQA1\*0401*, *DQB1\*0603*, *DPB1\*0202*, *ADRB1* and *NELL1*.<sup>6,7</sup> *LMP2* was associated with baseline damage, but not radiographic progression.<sup>8</sup> Previous study including 1537 AS cases identified two candidate single nucleotide polymorphisms (SNPs) (rs8092336 and rs1236913) which lies within *RANK* and *PTGS1* (prostaglandin-endoperoxide synthase 1).<sup>9</sup> However, unfortunately, there is no GWAS-scaled study that can suggest candidate loci involved in radiographic severity in AS.

Therefore, we conducted GWAS to identify both clinical and genetic factors associated with radiographic damage in Korean patients with AS.

## METHODS

### GWAS participants

All AS cases who satisfied the 1984 modified New York criteria were recruited from Hanyang University Hospital for Rheumatic Diseases and all patients provided informed consent.<sup>10</sup> Since we focused on radiographic damage followed by long-term disease course, only patients having available at least two complete sets of spine radiographs and

## Spondyloarthritis

**Table 1** Demographics of patients and clinical factors associated with radiographic damage in ankylosing spondylitis (AS)

Patients with AS (n=444)	Factors associated with final mSASSS*†		
	Estimate	SE	P value
Age at enrolment, years	31.4 (25.5–37.2)	0.007	0.003 $4.13 \times 10^{-2}$
Male sex	401 (90.3)	0.138	0.094 0.142
Symptom duration at enrolment, years	8.5 (4.0–14.0)	0.010	0.004 $1.14 \times 10^{-2}$
Follow-up duration, years	9.6 (7.9–11.3)	0.038	0.009 $2.14 \times 10^{-5}$
HLA-B27 positivity	427 (96.2)	0.087	0.130 0.504
Family history of AS	30 (6.8)	0.078	0.097 0.424
Uveitis	189 (42.6)	0.157	0.050 $1.95 \times 10^{-3}$
Peripheral joint involvement	199 (44.8)	-0.246	0.054 $6.85 \times 10^{-6}$
Inflammatory bowel disease	4 (0.9)	0.164	0.258 0.526
Psoriasis	15 (3.4)	-0.016	0.135 0.903
Ever smoker‡	292 (66.1)	0.130	0.059 $2.72 \times 10^{-2}$
Use of anti-TNF	277 (62.4)	0.056	0.053 0.287
Use of NSAIDs	439 (98.9)	0.220	0.232 0.343
Baseline mSASSS	7.7 (5.5–16.8)	0.796	0.035 $3.22 \times 10^{-75}$

Results are expressed as median (IQR) and n (%).

\*Log (mSASSS+1) value was used.

†Smoking data were available for 442 patients.

HLA, human leucocyte antigen; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAIDs, non-steroidal anti-inflammatory drug; TNF, tumour necrosis factor.

at least a 5-year time interval between baseline and the last radiograph sets were enrolled. The severity of structural damage on radiography was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS).<sup>11</sup>

We defined the index date as the first date of spine radiographs taken. All patients were observed until their last day of having complete set of spine radiographs or assessed as the highest possible mSASSS; 72. Radiographic progression rate was calculated as an increase in mSASSS units per year, and the final mSASSS was defined as the highest mSASSS during observational period.

### Gene data

Enrolled patients were genotyped with Korea Biobank Array (KoreanChip) which is optimised for the Korean population. The KoreanChip comprises >833 000 markers including >247 000 rare or functional variants, derived from sequencing data for over 2500 Koreans.<sup>12</sup> The genotyping data were filtered based on the quality control requirements that showed a high call rate ( $\geq 99\%$ ), no excessive heterozygosity,

**Table 2** The top 10 SNPs associated with higher final mSASSS score (n=442\*†)

SNP	Chr:Position	Beta	Gene	Function	P value
rs191573523	15:33 922 208	1.127	RYR3	Exonic	$1.00 \times 10^{-6}$
rs7518201	1:203 773 096	-0.149	ZC3H11A	Intronic	$1.00 \times 10^{-5}$
rs76789191	3:55 614 320	0.580	ERC2	Intronic	$1.21 \times 10^{-5}$
rs117416665	2:44 606 325	0.611	CAMKMT	Intronic	$2.36 \times 10^{-5}$
rs139358058	15:49 888 627	0.976	FAM227B	Intronic	$2.78 \times 10^{-5}$
rs7502336	17:78 281 770	-0.160	RNF213	Intronic	$2.78 \times 10^{-5}$
rs144589250	9:140 218 962	0.438	EXD3	Intronic	$3.17 \times 10^{-5}$
rs16915331	9:101 135 201	0.897	GABBR2	Intronic	$3.28 \times 10^{-5}$
rs11686946	2:128 394 955	0.182	MYO7B	Exonic	$4.08 \times 10^{-5}$
rs76838622	1:183 839 856	0.727	RGL1	Intronic	$4.36 \times 10^{-5}$

\*Smoking data were available for 442 patients.

†Log(mSASSS+1) value was used.

Chr, chromosome; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; SNP, single nucleotide polymorphism.

no cryptic first-degree relatives and sex consistency. SNPs were removed based on the following criteria: Hardy-Weinberg equilibrium  $<10^{-6}$ , genotype call rates  $<95\%$  and minor allele frequency  $<0.5\%$ .

### Statistical analysis

To identify clinical factors contributing to a higher final mSASSS, multiple linear regression analyses were performed. The analyses were performed using the SAS V9.2 statistical software (SAS Institute). P<0.05 was considered statistically significant. To identify genetic factors, multiple linear regression analyses were performed after adjusting for clinical factors. p< $5.00 \times 10^{-8}$  and p< $1.00 \times 10^{-5}$  were considered as the genome-wide significance threshold and suggestive level of association, respectively.

A nominal p<0.01 was used to filter SNPs from the GWAS analysis for pathway analysis after excluding intergenic genes. We used the DAVID online method based on the KEGG reference database (p<0.05; false discovery rate (FDR) < 0.05).

### Functional validation

#### Isolation of osteoprogenitor cells and differentiation

Human spine specimens were collected from 11 male patients who underwent spinal surgery. Seven of the patients satisfied the 1984 modified New York criteria for the classification of AS (median age 45.1 (28–61) years).<sup>10</sup> Four patients without inflammatory disease were enrolled as control group (median age 65.5 (56–73) years). Osteoprogenitors were isolated using an outgrowth method and stimulated to induce osteoblast differentiation, as described previously.<sup>13</sup>

#### Assessment of osteoblast differentiation

To investigate the impact of rhodamine B on osteoblast differentiation, AS-osteoprogenitor cells and control-osteoprogenitor cells were treated with vehicle or rhodamine B solution (Sigma, 02558) at the indicated dose (1 and 2  $\mu$ M/mL) during osteoblast differentiation. For the assessment of the matrix maturation phase, alkaline phosphates (ALP) and collagen deposition were assessed while Alizarin red staining (ARS), von Kossa (VON) and hydroxyapatite (HA) staining were used for the matrix mineralisation.

#### Knockdown of the RYR3 gene

Small interfering RNA (siRNA) against human RYR3 (siRYR3) or control (siCON) were synthesised by Genolution (Seoul, South Korea). The siRYR3 or siCON was transduced into SaOS2 cells for 48 hours using lipofectamine 3000 (Invitrogen, L3000008). Gene knockdown efficiency of transduced cells was analysed by reverse transcription-PCR (RT-PCR), immunoblotting and immunofluorescence. The siRNA sequences are shown as follows: RYR3 #1 sense, CCUUCAUCAUCAGUAUCUU and RYR3 #1 antisense UGAUACUGAGAGAUGAAGGUU; RYR3 #2 sense, CAUCUACAGACCAGAAUGAUU and RYR3 #2 antisense UCAUUCUGGUCUGUAGAUGUU; RYR3 #3 sense, GCAUJUGACCGCUAAAUGUUU and RYR3 #3 antisense ACAUUUAAGCGGUCAAUGCUU; RYR3 #4 sense, GGUA CUUCGAGCUGAUUAUUU and RYR3 #4 antisense AUAA UCAGCUCGAAGUACCUU; RYR3 #5 sense, CCUUCGAU CUGGUUUUCUAUUU and RYR3 #5 antisense AUAGAAC CAGAUCGAAGGUU; Control sense, CCUCGGCCGUU CCAUCAGGUAGUU and Control antisense, CUACCUGA UGGAACGGCACGAGGUU.

**Table 3** Pathway analysis using DAVID

KEGG pathway	Count	P value	Benjamini	FDR
Genes				
PI3K-Akt signalling pathway (hsa04151)	52	$2.21 \times 10^{-4}$	0.042	0.040
<i>FLT1, LAMC3, TNC, LAMC2, FGF1, FGF2, IFNA8, IGF1R, GHR, TNN, CREB3L2, TNR, JAK2, MAGI1, PDGFRB, CHUK, HGF, MAGI2, PRKCA, PRLR, CCNE2, COL4A1, ITGA8, COL6A3, SGK2, IFNAR1, LAMA1, LAMA4, LAMA3, PDGFB, LPAR1, FOXO3, EGFR, GNG2, RXRA, ERBB4, PPP2R3C, GNG7, PDGFC, ANGPT2, PTK2, CDK6, PPP2R2C, IL7, CDK4, ITGA11, RPS6KB2, BCL2, GNB3, PKN1, TEK, FGFR2</i>				

Akt,  $\alpha$  serine/threonine-protein kinase; FDR, false discovery rate; KEGG, kyoto encyclopaedia of genes and genomes; PI3K, phosphoinositide 3-kinase.

## Reverse transcription-PCR

Total RNA of transduced SaOS2 cells was extracted by TRIzol (Invitrogen, 10296028) and complementary DNA (cDNA) was amplified to perform RT-PCR following the manufacturer's protocol.<sup>14</sup> The following specific primers were used for RT-PCR: GAPDH, forward 5'-GTCAGTGGTGGACCTGACCT-3' and reverse 5'-AGGGGTCTACATGGCAACTG-3'; RYR3, forward 5'-GGACTTGGGAATCGCCTGTG-3' and reverse 5'-GCTCTGACAGATAGGGACTGTTC-3'.


## Immunoblotting and immunofluorescence

Transduced SaOS2 cells were carried out immunoblotting and immunofluorescence as described.<sup>14</sup> Anti-RYR3 (Invitrogen, PA5-77718) and anti-vinculin (Abclonal, A2752) were used. Immunoblotting and immunofluorescent images were visualised by the Uvitech System (Cambridge, UK) and Leica confocal microscopy (Wetzlar, Germany), respectively.

## RESULTS


## Patient characteristics

As shown in table 1, a total of 444 AS cases (male 90.3%) were included. The median patient age and symptom duration at enrolment were 31.4 (25.5–37.2) and 8.5 (4.0–14.0) years, respectively. Baseline mSASSS was 7.7 (5.5–16.8). Patients were observed for 9.6 (7.9–11.3) years. Within this period, mSASSS increased to 14.0 (7.0–36.8). The median age of patients was 40.8 (35.9–47.3) years when they have highest mSASSS during observational period. The median mSASSS progression rate was 0.43 (0.03–1.35) unit/year after excluding 8 patients having possible highest mSASSS; 72 at enrolment.



**Figure 1** Rhodamine B, a ligand of RYR3, promotes the matrix mineralisation in AS osteoprogenitors. Control (CON) and AS osteoprogenitors were differentiated into osteoblasts and continually stimulated by vehicle or rhodamine B with indicated dose during osteoblast differentiation. Osteogenic differentiation activity was assessed by (A) alkaline phosphates (ALP) and collagen (COL) staining, (B) ALP activity of (A), (C) Alizarin red staining (ARS) and ARS quantification, (D) von Kossa staining (VON) and mineralisation area (%), (E) hydroxyapatite (HA) staining and HA quantification.

## Spondyloarthritis



**Figure 2** RYR3 knockdown inhibits matrix mineralisation in SaOS2 cells. SaOS2 cells were transfected with siRNA against human RYR3 and control (CON), incubated for 48 hours, and differentiated for day 7. The stimulated cells were subjected to (A) RT-PCR, (B) immunoblotting, and (C) immunofluorescence. (D) Osteogenic differentiation activity was assessed by alkaline phosphates (ALP), collagen (COL), alizarin red staining (ARS), von Kossa staining (VON), and hydroxyapatite (HA). (E) Quantification data of figure D (n=4). Representative images are shown.

### Clinical and genetic factors associated with severe radiographic damage in patients with AS

The most influential clinical factor of final mSASSS was a higher baseline mSASSS ( $\beta=0.796$ ,  $p=3.22\times 10^{-75}$ ). Older age at enrolment, longer symptom duration and follow-up duration, uveitis and smoking were also related ( $\beta=0.007$ ,  $p=4.13\times 10^{-2}$ ;  $\beta=0.010$ ,  $p=1.14\times 10^{-2}$ ;  $\beta=0.038$ ,  $p=2.14\times 10^{-5}$ ;  $\beta=0.157$ ,  $p=1.95\times 10^{-3}$ ,  $\beta=0.130$ ,  $p=2.72\times 10^{-2}$ , respectively). Peripheral joint involvement was associated with less severe radiographic damage ( $\beta=-0.246$ ,  $p=6.85\times 10^{-6}$ ) (table 1).

After adjusting for clinical factors, we identified two novel loci reaching the suggestive level of association: one exonic SNP of *Ryanodine receptor 3* (RYR3) (rs191573523) ( $\beta=1.127$ ,  $p=1.00\times 10^{-6}$ ) and intronic SNP of *ZC3H11A* (rs7518201) ( $\beta=-0.149$ ,  $p=1.00\times 10^{-5}$ ). The top 10 SNPs associated with severe radiographic damage are available in table 2.

Pathway analyses highlighted the phosphoinositide 3-kinase (PI3K)-RAC- $\alpha$  serine/threonine-protein kinase (Akt) signalling pathway ( $p=2.21\times 10^{-4}$ , FDR=0.040) (table 3).

### Rhodamine B, a ligand of RYR3, promoted the matrix mineralisation in AS osteoprogenitors

For functional validation, human control osteoprogenitors and AS osteoprogenitors were induced to mature osteoblasts treated with vehicle or rhodamine B (figure 1). Collagen staining and ALP staining and activity were not affected by rhodamine B in both control and AS osteoprogenitors. And the ALP activity of AS osteoprogenitors was higher than that of control osteoprogenitors (figure 1A,B). However, we observed dose-dependent increases in intensity of ARS and VON stain, as well as ARS concentration and mineralisation area in human AS osteoprogenitors (figure 1C,D). Treatment of rhodamine B also increased HA in AS osteoprogenitors (figure 1E). Collectively, rhodamine B increased matrix mineralisation, but not matrix maturation during osteoblast differentiation in AS osteoprogenitors. However, the

rhodamine B-induced accelerated matrix mineralisation was not definitive in control osteoprogenitors (figure 1C-E).

### Knockdown of RYR3 inhibits matrix mineralisation

We established RYR3 knockdown in the SaOS2 cell line (figure 2). Knockdown of RYR3 was confirmed by RT-PCR, immunoblotting and immunofluorescence (figure 2A-C). RYR3 knockdown cells and control SaOS2 cells were stimulated to induce osteoblast differentiation. There was no significant difference in the intensity of collagen and ALP staining and ALP activity between RYR3 knockdown cells and control cells. However, the intensity of ARS and VON stain and HA were significantly decreased in RYR3 knockdown cells (figure 2D,E). These results suggest that the RYR3 knockdown has no effect on matrix maturation but inhibits matrix mineralisation during osteoblast differentiation.

### DISCUSSION

The present study identified both clinical and genetic factors associated with severe radiographic damage in AS. The clinical factors were largely comparable with those of previous studies, for example, baseline mSASSS, uveitis, smoking and peripheral joint involvement.<sup>8 15-19</sup> HLA-B27, the most important genetic risk factor for AS but repeatedly shown not to be linked with radiographic damage,<sup>9 20</sup> is not related to radiographic severity in this study. The most highlighted part of our study is the RYR3 gene extracted from GWAS data as a novel candidate gene for severe radiographic damage in AS. Further, rhodamine B (a ligand of RYR3)-induced matrix mineralisation was confirmed using human AS-osteoprogenitor cells. And knockdown of RYR3 inhibits matrix mineralisation in SaOS2 cell lines. In addition, PI3K-Akt signalling pathway was identified as candidate pathway of severe radiographic damage in AS.

RYR3 encoded by the RYR3 gene is a calcium release channel protein and regulates intracellular calcium homeostasis. The

Genotype Tissue Expression project from 17 382 samples and, 948 donors showed that *RYR3* gene is mainly expressed in musculoskeletal tissues (online supplemental figure 1). Although no previous study has investigated the relationship between *RYR3* and AS, there have been several studies that may support our results, including *RYR3* is related to calcification in patients with breast cancer and fibro-calcific aortic valve disease.<sup>21 22</sup> Moreover, transforming growth factor-beta (TGF $\beta$ ) reduces *RYR3* and inhibits matrix mineralisation in osteoblast differentiation.<sup>23 24</sup> Considering that TGF $\beta$  plays a role in inflammation and AS acting on the formation/repair of cartilage and bone, which are the major targets of AS,<sup>25</sup> our results might provide a clue to elucidate the underlying pathogenesis of radiographic damage in AS.

The PI3K-Akt signalling pathway, an intracellular signal transduction pathway involved in cell cycle and growth, is one of five significant signalling pathways in patients with AS compared with controls.<sup>26</sup> IL-8 and IL-37, which are closely related to AS, promote osteogenic differentiation via the PI3K-Akt signalling pathway.<sup>27 28</sup> Moreover, the PI3K-Akt signalling pathway was reported to promote inflammation and fibroblastic ossification in AS and has many downstream effects including activating NF- $\kappa$ B.<sup>13 29</sup> However, further study is required to identify the particular stage related to AS pathogenesis since this pathway participate in numerous biological processes.

The present study has a few limitations. First, the study population was relatively small and our study remains cross sectional focusing final mSASSS during observation period. Further longitudinal study using a large multiethnic cohort with longer follow-up period is needed since that the radiographic damage in very elderly patients might be fully reflect genetic factors. Second, the underlying mechanism of rhodamine B-induced accelerated matrix mineralisation and the link between inflammation and *RYR3* are not elucidated, which require further investigation. Lastly, though the functional study was conducted using human control-osteoprogenitor and AS-osteoprogenitor cells and *RYR3* knockdown SaOS2 cells. And the results can suggest that *RYR3* may play a role in spine ankylosis in AS. However, whether they have relevant *RYR3* SNP and its impact on *RYR3* protein are not confirmed in AS. We are planning further experiments on *RYR3* knockout cell line using clustered regular interspaced short palindromic repeats for more confirmative functional study.

To conclude, the radiographic damage in AS is affected by both clinical and genetic factors. We discovered *RYR3* as a novel candidate gene for severe radiographic progression in AS. Future effort should look closely into *RYR3* and *RYR3*-related mechanism on bone mineralisation to solve pathogenesis of spinal ankylosis in AS. Our results may pave a way for better personalised medicine by identifying patients at high risk of severe structural damage, but also open up new opportunities for drug development for radiographic damage in AS.

**Acknowledgements** The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Supplementary figure 1 in this manuscript were obtained from dbGaP accession number phs000424.v8.p2 in March 2022. The results of the study were selected for a poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress, Copenhagen, Denmark (1-4 June). The immunofluorescence images were analysed on Leica confocal installed at Hanyang LINC 3.0 Analytical Equipment Center (Seoul).

**Contributors** BN, SJ, S-YB and T-HK contributed to the study conception and design. BN and JHS assisted in identification and characterisation of patients. SL and KBJ performed the blinded reading of the radiographs. YP performed the statistical analyses. Y-SP contributed to collect human bone specimens. SJ is responsible for the experiments. BN and SJ drafted the manuscript. S-YB and T-HK reviewed and edited original draft. And all authors revised the paper and approved

the final version of the manuscript. T-HK is responsible for the overall content as the guarantor.

**Funding** This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R1A2C2004214 and 2021R1A6A1A03038899).

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Consent obtained directly from patient(s)

**Ethics approval** This study was carried out in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Hanyang University Hospital (IRB file No. 2014-05-002 and 2019-09-013). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.


#### ORCID iDs

Bora Nam <http://orcid.org/0000-0003-0215-3855>  
 Sungsin Jo <http://orcid.org/0000-0003-3034-5029>  
 So-Young Bang <http://orcid.org/0000-0003-4699-9350>  
 Tae-Hwan Kim <http://orcid.org/0000-0002-3542-2276>

#### REFERENCES

- Li Z, Brown MA. Progress of genome-wide association studies of ankylosing spondylitis. *Clin Transl Immunology* 2017;6:e163.
- Kim K, Bang S-Y, Lee H-S, et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. *Ann Rheum Dis* 2015;74:e13.
- Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat Genet* 2007;39:1329–37.
- International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* 2013;45:730–8.
- Kim K, Bang S-Y, Lee S, et al. An HLA-C amino-acid variant in addition to HLA-B\*27 confers risk for ankylosing spondylitis in the Korean population. *Arthritis Res Ther* 2015;17:1–6.
- Bartolomé N, Szczypiorska M, Sánchez A, et al. Genetic polymorphisms inside and outside the MHC improve prediction of as radiographic severity in addition to clinical variables. *Rheumatology* 2012;51:1471–8.
- Ward MM, Hendrey MR, Malley JD, et al. Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. *Arthritis Rheum* 2009;61:859–66.
- Haroon N, Maksymowich WP, Rahman P, et al. Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the spondyloarthritis research consortium of Canada cohort. *Arthritis Rheum* 2012;64:1119–26.
- Cortes A, Maksymowich WP, Wordsworth BP, et al. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. *Ann Rheum Dis* 2015;74:1387–93.
- Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. *Arthritis Rheum* 1984;27:361–8.
- Averns HL, Oxtoby J, Taylor HG, et al. Radiological outcome in ankylosing spondylitis: use of the stoke ankylosing spondylitis spine score (SASSS). *Br J Rheumatol* 1996;35:373–6.
- Moon S, Kim YJ, Han S, et al. The Korea biobank array: design and identification of coding variants associated with blood biochemical traits. *Sci Rep* 2019;9:1–11.

- 13 Jo S, Nam B, Lee YL, et al. The TNF-NF- $\kappa$ B-DKK1 axis promoted bone formation in the enthesis of ankylosing spondylitis. *J Rheum Dis* 2021;28:216–24.
- 14 Jo S, Lee JS, Nam B, et al. SOX9 $^+$  enthesis cells are associated with spinal ankylosis in ankylosing spondylitis. *Osteoarthritis Cartilage* 2022;30:280–90.
- 15 Koo BS, Oh JS, Park SY, et al. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. *Ann Rheum Dis* 2020;79:1327–32.
- 16 Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. *Ann Rheum Dis* 2018;77:63–9.
- 17 Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor  $\alpha$  inhibitors on radiographic progression in ankylosing spondylitis. *Arthritis Rheum* 2013;65:2645–54.
- 18 Deminger A, Klingberg E, Geijer M, et al. A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis. *Arthritis Res Ther* 2018;20:1–14.
- 19 Nam B, Koo BS, Choi N, et al. The impact of smoking status on radiographic progression in patients with ankylosing spondylitis on anti-tumor necrosis factor treatment. *Front Med* 2022;9:994797.
- 20 Akkoç N, Yarkan H, Kenar G, et al. Ankylosing spondylitis: HLA-B\*27-positive versus HLA-B\*27-negative disease. *Curr Rheumatol Rep* 2017;19:1–11.
- 21 Zhang L, Liu Y, Song F, et al. Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RyR3) affects breast cancer risk and calcification. *Proc Natl Acad Sci USA* 2011;108:13653–8.
- 22 Wilson RL, Sylvester CB, Wiltz DC, et al. The ryanodine receptor contributes to the lysophosphatidylcholine-induced mineralization in valvular interstitial cells. *Cardiovasc Eng Technol* 2020;11:316–27.
- 23 Neylon CB, Bryant SM, Little PJ, et al. Transforming growth factor-beta 1 regulates the expression of ryanodine-sensitive Ca2+ oscillations in cardiac myocytes. *Biochem Biophys Res Commun* 1994;204:678–84.
- 24 Nam B, Park H, Lee YL, et al. TGF $\beta$ 1 suppressed matrix mineralization of osteoblasts differentiation by regulating SMURF1-C/EBP $\beta$ -DKK1 axis. *Int J Mol Sci* 2020;21:9771.
- 25 Jaakkola E, Crane AM, Laiho K, et al. The effect of transforming growth factor beta1 gene polymorphisms in ankylosing spondylitis. *Rheumatology* 2004;43:32–8.
- 26 Huang D, Liu J, Wan L, et al. Identification of lncRNAs associated with the pathogenesis of ankylosing spondylitis. *BMC Musculoskelet Disord* 2021;22:1–9.
- 27 Ye C, Zhang W, Hang K, et al. Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/Akt signaling pathway. *Cell Death Dis* 2019;10:1–12.
- 28 Yang A, Lu Y, Xing J, et al. IL-8 enhances therapeutic effects of BMSCs on bone regeneration via CXCR2-mediated PI3K/Akt signaling pathway. *Cell Physiol Biochem* 2018;48:361–70.
- 29 Qin X, Jiang T, Liu S, et al. Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: an in vitro study. *J Cell Biochem* 2018;119:1074–82.



**Supplementary Figure 1. Bulk tissue gene expression for RYR3.**

RYR3 gene is mainly expressed in musculoskeletal tissues.

Supplementary figure 1 was obtained from dbGaP accession number phs000424.v8.p2 in March 2022. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.